Patients with sporadic and familial amyotrophic lateral sclerosis found value in genetic testing

Publication
Affiliates	Karin N. Wagner [1], Haikady N. Nagaraja [2], Dawn C. Allain [1,3], Adam Quick [4], Stephen J. Kolb [4,5], Jennifer Roggenbuck [3,4] [1] Genetic Counseling Graduate Program, The Ohio State University [2] Division of Biostatistics, College of Public Health, The Ohio State University [3] Division of Human Genetics, Wexner Medical Center, The Ohio State University [4] Department of Neurology, Wexner Medical Center, The Ohio State University [5] Department of Biological Chemistry and Pharmacy Wexner Medical Center, The Ohio State University
Journal	Molecular Genetics & Genomic Medicine
Summary	For both sporadic and familial ALS, there is growing evidence of the role of genetics. What is unclear, is the role of genetic testing in the care of the PALS. Using outreach via the National ALS Registry, data was collected on patient access, attitudes, and experience with ALS genetic testing from 449 survey respondents. Of these 449 respondents, 156 were offered testing and 105 completed testing, most of whom have familial ALS. Results from this study indicate that patients with ALS found value in clinical genetic testing.
Link to paper	Find the paper hereexternal icon!

Page last reviewed: July 14, 2021